Board Member
Ptc Therapeutics, Inc. (PTCT)Equibles does not estimate personal net worth.
Get an email with a short summary when Ptc Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get PTCT alertsMatthew B. Klein is recorded as CEO at Ptc Therapeutics, Inc. (PTCT) since March 22, 2023 and Board Member at Ptc Therapeutics, Inc. (PTCT). The newest filing on record that lists Matthew B. Klein as Board Member and CEO at Ptc Therapeutics, Inc. (PTCT) is dated April 26, 2023. Ptc Therapeutics, Inc. reported in an 8-K filed March 24, 2023 that Matthew B. Klein was appointed Chief Executive Officer and President and a member of the Board, effective March 22, 2023. Matthew B. Klein has spoken on 2 earnings calls and 2 other investor events across 1 company, most recently for Ptc Therapeutics, Inc. on July 30, 2026. Ptc Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Ptc Therapeutics, Inc. includes Dr. Matthew B. Klein (CEO and Board Member), Matthew Klein (CEO and Board Member), Michael Schmertzler (CFO) and 7 others.
“On March 22, 2023, the Board of Directors (the "Board") of PTC Therapeutics, Inc. (the "Company") appointed Dr. Matthew B. Klein, age 51, as Chief Executive Officer and President and a member of the Board, effective as of March 22, 2023.”
“I'm excited to share the results of another quarter of outstanding execution across the company. Starting with revenue, we achieved another record quarter with total revenue of $361 million, including $239 million of product revenue driven by continued strong global supply and sales.”
“Look, we're really excited with how the launch has gone to date and for what we see as continued growth. We expect to have continued growth in the U.S. as well as later in the year contributions ex-U.S. given our global footprint and already the number of global approvals that we have.”
“PTC is a global biopharmaceutical company that discovers, develops, and commercializes therapies for diseases of a high-end met need.”
“2025 was a year of many significant successes for PTC. positioning us well for 2026 and beyond. I'll start by reviewing the highlights of 2025 and then share our key objectives for 2026.”
2023-03-22–present
Last confirmed April 26, 2023
Start not stated–present
Last confirmed April 26, 2023
Biotechnology · Healthcare
Board Member, CEO
2023-03-22–present
